MLTX
MoonLake Immunotherapeutics15.34
+1.02+7.12%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
1.09BP/E (TTM)
-Basic EPS (TTM)
-3.33Dividend Yield
0%Recent Filings
10-K
FY2025 results
MoonLake Immunotherapeutics' 10-K for FY2025 ended December 31, 2025 lacks financial statements, primary metrics, or quarterly breakdowns, so topline, profitability, and momentum remain undisclosed. No revenue, EPS, margins, cash flows, or segment results appear in the provided filing excerpt. Liquidity, capital allocation, and outlook not detailed. Q4 trends impossible to assess. Clinical trial delays threaten momentum.
8-K
Strong Phase 2 axSpA data
MoonLake amended its loan agreement with Hercules on February 20, 2026, drawing $25 million while unlocking up to $400 million more in non-dilutive funding tied to sonelokimab milestones in psoriatic arthritis and hidradenitis suppurativa. Phase 2 S-OLARIS trial hit big: 81% ASAS40 response at week 12. Cash stands at $394 million.
8-K
FDA clears SLK BLA path
MoonLake scored positive FDA feedback from its Type B meeting, greenlighting BLA submission for sonelokimab in hidradenitis suppurativa using existing VELA-1, VELA-2, and MIRA trial data—no new HS trials needed. BLA stays on track for H2 2026. Investor Day set for February 23. FDA nixed mechanistic evidence as confirmatory.
8-K
MoonLake launches $75M share offering
8-K
Sonelokimab PPP data impresses
MoonLake reported Q3 2025 results with $380.5M cash runway into H2 2027, despite R&D expenses jumping to $60.6M from clinical ramp-up. Sonelokimab shone in Phase 2 LEDA trial for palmoplantar pustulosis, hitting 64% mean PPPASI reduction and 39% PPPASI75 at week 16. Cash fuels busy pipeline. FDA meeting set for Dec 15 on HS BLA.
IMA
ImageneBio, Inc.
6.25+0.08
IMUC
EOM Pharmaceutical Holdings Inc
0.18+0.00
IMUX
Immunic, Inc.
0.60-0.01
IMVT
Immunovant, Inc.
26.61+0.61
MRKR
Marker Therapeutics, Inc.
1.27-0.12
SABS
SAB Biotherapeutics, Inc.
3.99-0.01
SCNI
Scinai Immunotherapeutics Ltd.
0.84-0.04
XBIT
XBiotech Inc.
2.45-0.08
XLO
Xilio Therapeutics, Inc.
0.65+0.00
ZURA
Zura Bio Limited
4.12+0.05